ISTH 2025 Spotlight: HOPE-B Trial Highlights Sustained Efficacy of Gene Therapy for Hemophilia B
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X:
“ISTH 2025 Highlight: Our HOPE-B study results were brilliantly presented by Dr. Steven Pipe at ISTH 2025, showcasing 4-year durability data in haemophilia B gene therapy.
Study Overview
The phase 3 HOPE-B trial evaluated a single IV dose of etranacogene dezaparvovec (AAV5-FIX Padua) in adults with haemophilia B (FIX ≤2 IU/dL).
N = 54; Responders = 52
Key Efficacy Results
· ↓ 81% in annualized bleeding rate (ABR) (months 7–48 vs. baseline)
· ↓ 90% in ABR at Year 4 vs. lead-in period
· ↓ 98% in mean exogenous FIX use (IU/year) at Year 4
· 98% of participants remained prophylaxis-free through 4 years
· 37% required zero exogenous FIX infusions over 4 years
Factor IX (FIX) Expression
· Mean FIX activity: 37.4% at Year 4
· 83% of responders maintained FIX levels 12–100 IU/dL at 4 years
· Stable expression over 4 years → near-normal hemostasis
Safety Profile
· 96 treatment-related adverse events (TRAEs) over 4 years
· 96% occurred in first 6 months
· Most frequent: ALT↑ (18.5%), headache, flu-like illness
· No FIX inhibitors
· No thrombotic events
· No AAV5-associated genotoxicity or persistent late hepatotoxicity
Clinical Implications
· Single-dose gene therapy led to durable FIX expression and sustained reduction in bleeding and FIX use for ≥4 years
· Majority achieved and maintained prophylaxis freedom
· Favorable safety profile with minimal late events
· Ongoing follow-up remains important for long-term assessment
Congratulations to Steve Pipe and the co-authors.”
Stay updated with Hemostasis Today.
-
Jul 16, 2025, 17:23ISTH 2025 Spotlight: HOPE-B Trial Highlights Sustained Efficacy of Gene Therapy for Hemophilia B
-
Jul 16, 2025, 15:00Together with Dr. Bethany Samuelson Bannow – Let’s Keep Hematology Moving Forward
-
Jul 16, 2025, 14:58Donate Today to Advance Thrombosis Awareness and Research
-
Jul 16, 2025, 14:57ISTH SSC Launches Survey on Antithrombotic Therapy in Brain Tumor Patients
-
Jul 16, 2025, 14:52ASH Expands Access to Educational Resources in LMICs
-
Jul 16, 2025, 11:06Why Pain Feels Different for Everyone - The Guardian
-
Jul 15, 2025, 18:24Time and Severe Hypoperfusion: 2 Threats for Hemorrhagic Transformation in Stroke
-
Jul 15, 2025, 15:48Managing CVT in Pregnancy: Balancing Risks and the Role of Antithrombotic Prophylaxis
-
Jul 15, 2025, 07:37Triple Therapy Breakthrough: Corticosteroids, IVIG, and Platelet Transfusions Transform Management of Critical ITP Bleeding - Blood Journals Portfolio
-
Jul 14, 2025, 18:253 Valuable Takeaways from the ANGEL-REBOOT Trial for ICAS-O Stroke
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 15, 2025, 17:002022 Chemistry Laureate Carolyn Bertozzi Shares Inspiring Advice for Young Scientists
-
Jul 15, 2025, 16:42A 200+ Year Historical Review of Women and Hemophilia: Shifting Perspectives
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs
-
Jul 6, 2025, 15:02Patients as Experts: EHC Calls for Early Involvement in HTA Systems